<DOC>
	<DOC>NCT02005458</DOC>
	<brief_summary>This study is to examine which dose of YPEG-rhG-CSF, once-per-cycle, has similar efficacy and safety, comparing to PEG-rhG-CSF, once-per-cycle, in chemotherapy-induced neutropenia</brief_summary>
	<brief_title>Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Diagnosis of nonsmall cell lung cancer or Breast cancer, and adequate for carboplatin combined with taxol or cyclophosphamide combined with pharmorubicin chemotherapy Karnofsky Score ≥ 70 Life Expectancy &gt; 3 months Age: 18～70yrs. Peripheral blood test: WBC≥3.5×106/mm3, PLT≥100×106/mm3, ANC≥1.5×106/mm3; Normal bone marrow function; Bone marrow biopsy shows active hematopoietic without cancer cells. Normal coagulation function, no evidences of hemorrhage tendency. No exiting diseases or condition that may influence drug absorption, distribution, metabolism, and excretion. Adequate liver, cardiac, kidney function. Indicators of liver function test ≤ 2.5ULN, Indicators of kidney function test ≤ 1ULN Understand and voluntarily sign an informed consent form. Pregnant or lactating females Evidence of tumor metastasis in bone marrow Lack insight due to tumor metastasis in the central nervous system Prior bone marrow transplant or stem cell transplant Infective symptom before enrollment into this study Other malignancy history Known hypersensitivity to any component of the drug(e.g. rhGCSF) that to be administered Subject enrolled in any other investigational drug or device trial within 3 months of informed consent date Drug abuser or alcoholist Prior radiotherapy or expected to received radiotherapy Unstable or uncontrolled cardiac or hypertension Other conditions which in the opinion of the investigator preclude enrollment into the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Febrile neutropenia</keyword>
	<keyword>PEG-rhG-CSF</keyword>
	<keyword>Myelosuppressive chemotherapy</keyword>
</DOC>